These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 27762587)
1. Intracellular fate of polymer therapeutics investigated by fluorescence lifetime imaging and fluorescence pattern analysis. Panek J; Koziolova E; Stepanek P; Etrych T; Janouskova O Physiol Res; 2016 Oct; 65(Suppl 2):S217-S224. PubMed ID: 27762587 [TBL] [Abstract][Full Text] [Related]
2. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin. Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482 [TBL] [Abstract][Full Text] [Related]
3. Two step mechanisms of tumor selective delivery of N-(2-hydroxypropyl)methacrylamide copolymer conjugated with pirarubicin via an acid-cleavable linkage. Nakamura H; Etrych T; Chytil P; Ohkubo M; Fang J; Ulbrich K; Maeda H J Control Release; 2014 Jan; 174():81-7. PubMed ID: 24269967 [TBL] [Abstract][Full Text] [Related]
4. Nanotherapeutics with anthracyclines: methods of determination and quantification of anthracyclines in biological samples. Koziolova E; Janouskova O; Chytil P; Studenovsky M; Kostka L; Etrych T Physiol Res; 2015; 64(Suppl 1):S1-10. PubMed ID: 26447590 [TBL] [Abstract][Full Text] [Related]
5. Comparison between linear and star-like HPMA conjugated pirarubicin (THP) in pharmacokinetics and antitumor activity in tumor bearing mice. Nakamura H; Koziolová E; Etrych T; Chytil P; Fang J; Ulbrich K; Maeda H Eur J Pharm Biopharm; 2015 Feb; 90():90-6. PubMed ID: 25460144 [TBL] [Abstract][Full Text] [Related]
6. Differences in the intracellular fate of free and polymer-bound doxorubicin. Hovorka O; St'astný M; Etrych T; Subr V; Strohalm J; Ulbrich K; Ríhová B J Control Release; 2002 Apr; 80(1-3):101-17. PubMed ID: 11943391 [TBL] [Abstract][Full Text] [Related]
7. Phasor-Fluorescence Lifetime Imaging Microscopy Analysis to Monitor Intercellular Drug Release from a pH-Sensitive Polymeric Nanocarrier. Zhou T; Luo T; Song J; Qu J Anal Chem; 2018 Feb; 90(3):2170-2177. PubMed ID: 29336550 [TBL] [Abstract][Full Text] [Related]
8. Thermal and pH responsive polymer-tethered multifunctional magnetic nanoparticles for targeted delivery of anticancer drug. Sahoo B; Devi KS; Banerjee R; Maiti TK; Pramanik P; Dhara D ACS Appl Mater Interfaces; 2013 May; 5(9):3884-93. PubMed ID: 23551195 [TBL] [Abstract][Full Text] [Related]
9. A tumor-targeted polymer theranostics platform for positron emission tomography and fluorescence imaging. Koziolová E; Goel S; Chytil P; Janoušková O; Barnhart TE; Cai W; Etrych T Nanoscale; 2017 Aug; 9(30):10906-10918. PubMed ID: 28731080 [TBL] [Abstract][Full Text] [Related]
10. ATP-Responsive and Near-Infrared-Emissive Nanocarriers for Anticancer Drug Delivery and Real-Time Imaging. Qian C; Chen Y; Zhu S; Yu J; Zhang L; Feng P; Tang X; Hu Q; Sun W; Lu Y; Xiao X; Shen QD; Gu Z Theranostics; 2016; 6(7):1053-64. PubMed ID: 27217838 [TBL] [Abstract][Full Text] [Related]
11. Intracellular Dynamic Disentangling of Doxorubicin Release from Luminescent Nanogold Carriers by Fluorescence Lifetime Imaging Microscopy (FLIM) under Two-Photon Excitation. Suarasan S; Craciun AM; Licarete E; Focsan M; Magyari K; Astilean S ACS Appl Mater Interfaces; 2019 Feb; 11(8):7812-7822. PubMed ID: 30707545 [TBL] [Abstract][Full Text] [Related]
12. Using fluorescence lifetime imaging microscopy to monitor theranostic nanoparticle uptake and intracellular doxorubicin release. Basuki JS; Duong HT; Macmillan A; Erlich RB; Esser L; Akerfeldt MC; Whan RM; Kavallaris M; Boyer C; Davis TP ACS Nano; 2013 Nov; 7(11):10175-89. PubMed ID: 24131276 [TBL] [Abstract][Full Text] [Related]
13. Using Peptide Aptamer Targeted Polymers as a Model Nanomedicine for Investigating Drug Distribution in Cancer Nanotheranostics. Zhao Y; Houston ZH; Simpson JD; Chen L; Fletcher NL; Fuchs AV; Blakey I; Thurecht KJ Mol Pharm; 2017 Oct; 14(10):3539-3549. PubMed ID: 28880092 [TBL] [Abstract][Full Text] [Related]
14. The effect of size and polymer architecture of doxorubicin-poly(ethylene) glycol conjugate nanocarriers on breast duct retention, potency and toxicity. Gu Z; Gao D; Al-Zubaydi F; Li S; Singh Y; Rivera K; Holloway J; Szekely Z; Love S; Sinko PJ Eur J Pharm Sci; 2018 Aug; 121():118-125. PubMed ID: 29698706 [TBL] [Abstract][Full Text] [Related]
15. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. He Y; Su Z; Xue L; Xu H; Zhang C J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977 [TBL] [Abstract][Full Text] [Related]
16. Poly(2-ethyl-2-oxazoline) conjugates with doxorubicin for cancer therapy: In vitro and in vivo evaluation and direct comparison to poly[N-(2-hydroxypropyl)methacrylamide] analogues. Sedlacek O; Monnery BD; Mattova J; Kucka J; Panek J; Janouskova O; Hocherl A; Verbraeken B; Vergaelen M; Zadinova M; Hoogenboom R; Hruby M Biomaterials; 2017 Nov; 146():1-12. PubMed ID: 28892751 [TBL] [Abstract][Full Text] [Related]
17. Hepatic drug targeting: phase I evaluation of polymer-bound doxorubicin. Seymour LW; Ferry DR; Anderson D; Hesslewood S; Julyan PJ; Poyner R; Doran J; Young AM; Burtles S; Kerr DJ; J Clin Oncol; 2002 Mar; 20(6):1668-76. PubMed ID: 11896118 [TBL] [Abstract][Full Text] [Related]
18. The structure of polymer carriers controls the efficacy of the experimental combination treatment of tumors with HPMA copolymer conjugates carrying doxorubicin and docetaxel. Šírová M; Strohalm J; Chytil P; Lidický O; Tomala J; Říhová B; Etrych T J Control Release; 2017 Jan; 246():1-11. PubMed ID: 27940304 [TBL] [Abstract][Full Text] [Related]
19. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
20. In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio. Baabur-Cohen H; Vossen LI; Krüger HR; Eldar-Boock A; Yeini E; Landa-Rouben N; Tiram G; Wedepohl S; Markovsky E; Leor J; Calderón M; Satchi-Fainaro R J Control Release; 2017 Jul; 257():118-131. PubMed ID: 27374630 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]